Overview of α1-adrenoceptor antagonism and recent advances in hypertensive therapy

American Journal of Hypertension

Volumn 9, Issue 11, 1996, Pages

  Veelken, Roland ^a   Schmieder, Roland E ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

adrenoceptor antagonists; antihypertensive therapy; hypertension

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUNAZOSIN; METOPROLOL;

CONFERENCE PAPER; GLOMERULUS FILTRATION RATE; GLUCOSE TOLERANCE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIPID METABOLISM; PRIORITY JOURNAL;

EID: 0029803532     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/0895-7061(96)00289-0     Document Type: Conference Paper

References (76)

1. Abboud FM: The sympathetic system in hypertension. State-of-the-art review. Hypertension 1982;4:208-225.
2. Folkow B: Sympathetic nervous control of blood pressure. Role in primary hypertension. Am J Hypertens 1989;2:103S-111S.
3. Triggle CR, Tabrizchi R: Changes in vascular smooth muscle function in hypertension. Chin Med J Engl 1993; 106:250-257.
4. Insel PA: Adrenergic receptors - evolving concepts and clinical implications. N Engl J Med 1996;334:580-585.
5. Ahlquist RP: A study of the adrenotropic responses. Am J Physiol 1948;153:586-600.
6. Bylund DB, Eikenberg DC, Hieble JP, et al: International Union on Pharmacology nomenclature of adrenoceptors. Pharmacol Rev 1994;46:121-136.
7. Berthelsen S, Pettinger WA: A functional basis for classification of α-adrenergic receptors. Life Sci 1977; 21:595-606.
8. Ariens AE, Simonis AM: Physiological and pharmacological aspects of adrenergic classification. Biochem Pharmacol 1983;32:1539-1545.
9. 1-Adrenegic receptor subtypes. Ann Rev Pharmacol Toxicol 1994;34:117-133.
10. 1 adrenoceptor classification: sharpening Occam's razor. Trends Pharmacol Sci 1994;15:167-170.
11. Simon MI, Strathmann MP, Gautam N: Diversity of G proteins in signal transduction. Science 1991;252:802-808.
12. Hescheler J, Schultz G: Heterotrimeric G proteins involved in the modulation of voltage-dependent calcium channels of neuroendocrine cells. NY Acad Sci 1994;733:306-312.
13. Clapham DE, Neer EJ: New roles for G-protein beta gamma-dimers in transmembrane signalling. Nature 1993;365:403-406.
14. Post SR, Hilal-Dandan R, Urasawa K, et al: Quantification of signaling components and amplification in the b-adrenergic receptor-adenyl cyclase pathway in isolated adult rat ventricular myocytes. Biochem J 1995; 311:75-80.
15. Luft FC, Veelken R, Becker H, et al: Effects of urapidil, clonidine and prazosin on sympathetic tone in conscious rats. Hypertension 1986;8:303-311.
16. Khoury AF, Kaplan NM: Alpha-blocker therapy of hypertension. An unfulfilled promise. JAMA 1991; 266:394-398.
17. Pollare T, Lithell H, Selinus I, Berne C: Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988;31:415-420.
18. Pool JL: Effects of doxazosin on serum lipids: a review of the clinical data and molecular basis for altered lipid metabolism. Am Heart J 1991;121:251-259.
19. Schmieder RE, Schubel H-P, Gatzka C, et al: Regression tüber Endorganshäden durch antihypertensive Therapie: Bunazosin retard und Metoprolol im Veigleich. Nieren-Hochdruckkr (in press).
20. Schmieder RE, Rockstroh JK: Obesity and hypertension. Curr Opin Nephrol Hypertens 1994;3:546-549.
21. van Zwieten PA: Basic pharmacology of alpha-adrenoceptor antagonists and hybrid drugs. J Hypertens 1988; 6(suppl):S3-S11.
22. van Zwieten PA. Antihypertensive drugs interacting with alpha- and beta-adrenoceptors. A review of basic pharmacology. Drugs 1988;35(suppl 6):6-19.
23. Graham RM, Thornell IR, Gain JM, et al: Prazosin: the first-dose phenomenon. Br Med J 1976;27(Nov): 1293-1294.
24. Semple PF, Thoren P, Lever AF: Vasovagal reactions to cardiovascular drugs: the first dose effect. J Hypertens 1988;6:601-606.
25. Schmieder RE: Nephroprotection by antihypertensive agents. J Cardiovasc Pharmacol 1994;24(suppl 2):S55-S64.
26. Devereux RB, Pickering TG, Harshfield GA: Left ventricular hypertrophy in patients with hypertension: importance of blood pressure response to regularly recurring stress. Circulation 1983;68:470-476.
27. Rowlands DB, Ireland RE, Stallard TE: Assessment of left ventricular mass and its response by antihypertensive treatment. Lancet 1982;i:467-470.
28. Eliot RS, Buell JC: The role of CNS in cardiovascular diosorder. Hosp Pract 1983;18:189-199.
29. Falkner B, Kushner H, Onesti G, Angelakos ET: Cardiovascular characteristics in adolescents who develop essential hypertension. Hypertension 1981;3:521-527.
30. Schmieder RE, Rüdel H, Schächinger H, Schulte W: Impact of angiotensin enzyme inhibition on the hemodynamic profile during laboratory stress tests. J Hum Hypertens 1992;6:227-232.
31. Schmieder RE, Gatzka C, Schobel H, et al: Renal hemodynamic response to stress is influenced by ACE-inhibitors. Clin Nephrol 1994;381-388.
32. Mancia G, Zanchetti A: Blood pressure variability, in Zanchetti A, Tarazi R (eds): Handbook of Hypertension, Vol. 7: Pathophysiology of Hypertension: Cardiovascular System. Elsevier, Amsterdam, 1986, pp 125-552.
33. Schmieder R, Ruddel H, Langewitz W, et al: The influence of monotherapy with oxprenolol and nitrendipine on ambulatory blood pressure in hypertensives. Clin Exp Hypertens [A] 1985;7:445-454.
34. Ruddel H, Langewitz W, Schachinger H, et al: Hemodynamic response patterns to mental stress: diagnostic and therapeutic implications. Am Heart J 1988; 116:617-627.
35. Parati G, Pomidossi G, Casadei R, et al: Comparison of the cardiovascular effects of different laboratory stressors and their relationship with blood pressure variability. J Hypertens 1988;6:481-488.
36. Schmieder RE, Gatzka C, Schobel H, et al: Renal hemodynamic response to stress is influenced by ACE-inhibitors. Clin Nephrol 1994;42:381-388.
37. Schmieder RE, Rueddel H, Neus H, et al: Disparate hemodynamic responses to mental challenge after antihypertensive therapy with beta blockers and calcium entry blockers. Am J Med 1987;82:11-16.
38. Grossman E, Messerli FH, Oren S, et al: Disparate cardiovascular response to stress tests during isradipine and fosinopril therapy. Am J Cardiol 1993;72:574-579.
39. Langenfeld ME, Bräutigam M, Weidinger G, et al: Antihypertensive efficacy and orthostatic tolerance of bunazosin versus nitrendipin. J Hum Hypertens (in press).
40. Collins R, Peto R, MacMahon S, et al: Blood pressure, stroke, and coronary heart disease. Lancet 1990; 335:827-838.
41. Schobel HP, Langenfeld ME, Gatzka CD, Schmieder RE: Treatment and post-treatment effects of alpha- versus beta-receptorblockers on left ventricular structure and function in essential hypertension. Am Heart J (in press).
42. Gatzka C, Schobel HP, Schmieder RE: Disparate hemodynamic responses to stress under treatment with a and b adrenoceptor blockers: results of a double-blind randomized study (abst). Am J Hypertens 1996;9(5, suppl):154A.
43. Smyth P, Pringle S, Jackson G, Lorimer AR: 24-Hour control of blood pressure by once daily doxazosin: a multicentre double-blind comparison with placebo. Eur J Clin Pharmacol 1988;34:613-618.
44. Sasaki J, Koga S, Uzawa H, Arakawa K: Comparative effects of bunazosin and propranolol on serum lipids and apolipoproteins in patients with essential hypertension. Int J Clin Pharmacol Ther Toxicol 1989;27:402-407.
45. Suzuki M, Hirose J, Asakura Y, et al: Insulin insensitivity in nonobese, nondiabetic essential hypertension and its improvement by an alpharblocker (bunazosin). Am J Hypertens 1992;5:869-874.
46. 1 Rezeptoren. Klinischer Vergleich von Bunazosin und Doxazosin. Nieren Hochdruckkr 1994;2:63-69.
47. Rieckert H, Weidinger G, Schardt FW: Orthostatic hypotension during antihypertensive treatment with bunazosin and prazosin. Drug Invest 1993;5:327-333.
48. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group [see comments]. JAMA 1991;265:3255-3264.
49. Dahlof B, Lindholm LH, Hansson L, et al: Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338:1281-1285.
50. MacMahon S, Peto R, Cutler J, et al: Blood pressure, stroke, and coronary heart disease. Lancet 1990; 335:765-774.
51. Holzgreve H: Where now the diuretics in antihypertensive treatment? Eur Heart J 1992;13(suppl G):104-108.
52. Pollare T, Lithell H, Berne C: A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989;321:868-873.
53. Pollare T, Lithell H, Morlin C, et al: Metabolic effects of diltiazem and atenolol: results from a randomized, double-blind study with parallel groups. J Hypertens 1989;7:551-559.
54. Lithell H, Haglund K, Granath F, Ostman J: Are effects of antihypertensive treatment on lipoproteins merely "side-effects"? A comparison of prazosin and metoprolol. Acta Med Scand 1988;223:531-536.
55. Ferrara LA, Di Marino L, Russo O, et al: Doxazosin and captopril in mildly hypercholesterolemic hypertensive patients. The Doxazosin-Captopril in Hypercholesterolemic Hypertensives Study. Hypertension 1993; 21:97-104.
56. Carruthers G, Dessain P, Fodor G, et al: Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension. The Alpha Beta Canada Trial Group. Am J Cardiol 1993;71:575-581.
57. Rabkin SW: Mechanisms of action of adrenergic receptor blockers on lipids during antihypertensive drug treatment. J Clin Pharmacol 1993;33:286-291.
58. Bönner G: Hyperinsulinemia, insulin resistance, and hypertension. J Cardiovasc Pharmacol 1994;24(suppl 2):S39-S49.
59. Landsberg L: Hyperinsulinemia: possible role in obesity-induced hypertension. Hypertension 1992;19:161-166.
60. Draznin B, Sussman KE, Eckel RH, et al: Possible role of cytosolic free calcium concentrations in mediating insulin resistance of obesity and hyperinsulinemia. J Clin Invest 1988;82:1848-1852.
61. Scherrer U, Nussberger J, Torriani S, et al: Effect of weight reduction in moderately overweight patients on recorded ambulatory blood pressure and free cytosolic platelet calcium. Circulation 1991;83:552-558.
62. Casale PN, Devereux RB, Milner M, et al: Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986;105:173-178.
63. Koren MJ, Devereux RB, Casale PN, et al: Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114:345-352.
64. Motz W, Klepzig M, Strauer BE: Regression of cardiac hypertrophy: experimental and clinical results. J Cardiovasc Pharmacol 1987;10(suppl 6):S148-S152.
65. Schmieder RE, Martus P, Klingbeil A: Reversal of left ventricular hypertrophy in essential hypertension. JAMA 1996;275:1507-1513.
66. 1 adrenergic response. J Clin Invest 1983;72:732-738.
67. Yamori Y, Tarazi RC, Ooshima A: Effect of beta-receptor-blocking agents on cardiovascular structural changes in spontaneous and noradrenaline-induced hypertension in rats. Clin Sci 1980;59(suppl 6):457s-460s.
68. Freis ED: Hemodynamics of hypertension. Phys Rev 1960;40:27-53.
69. Schmieder RE, Schachinger H, Messerli FH: Accelerated decline in renal perfusion with aging in essential hypertension. Hypertension 1994;23:351-357.
70. Fouad Tarazi FM, Liebson PR: Echocardiographic studies of regression of left ventricular hypertrophy in hypertension. Hypertension 1987;9:1165-1168.
71. Wollam GL, Hall WD, Porter VD, et al: Time course of regression of left ventricular hypertrophy in treated hypertensive patients. Am J Med 1983;75:100-110.
72. Yurenev AP, Dyakonova HG, Novikov ID, et al: Management of essential hypertension in patients with different degrees of left ventricular hypertrophy. Multicenter trial. Am J Hypertens 1992;5:182S-189S.
73. 3H] E-643-binding to alpha adrenoceptors. Jpn J Pharmacol 1982;32:181-187.
74. Ablad B, Borg KO, Carlsson E, et al: Animal and human pharmacological studies on metoprolol - a new selective beta-1-receptor antagonist. Acta Pharmacol Toxicol 1975;36(suppl 5):5-12.
75. Anderton JL, Gill M, Notghi A: Renal haemodynamic effects of bunazosin retard and prazosin in mild to moderately hypertensive patients with normal or moderately impaired renal function. Nephrol Dial Transplant 1994;9:607-612.
76. Simpson P. Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha 1 adrenergic response. J Clin Invest 1983;72:732-738.